Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniel G Stover

Showing results (121-130 of 148) with videos related to

Pageof 15
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2024
Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast CancerStefania Morganti, Christopher J Gibson, Qingchun Jin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2019
Correction: ER<sup>+</sup> Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 InhibitorsAngel L Guerrero-Zotano, Thomas P Stricker, Luigi Formisano, et al.
Nature Communications|January 25, 2023
Author Correction: A framework for clinical cancer subtyping from nucleosome profiling of cell-free DNAAnna-Lisa Doebley, Minjeong Ko, Hanna Liao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2018
ER<sup>+</sup> Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 InhibitorsAngel L Guerrero-Zotano, Thomas P Stricker, Luigi Formisano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 4, 2018
Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast CancerDaniel G Stover, Heather A Parsons, Gavin Ha, et al.
Nature Communications|December 3, 2022
A framework for clinical cancer subtyping from nucleosome profiling of cell-free DNAAnna-Lisa Doebley, Minjeong Ko, Hanna Liao, et al.
Nature Medicine|June 9, 2016
Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastasesJing Ni, Shakti H Ramkissoon, Shaozhen Xie, et al.
Cell Reports|November 24, 2016
CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast CancerShawn F Johnson, Cristina Cruz, Ann Katrin Greifenberg, et al.
The Oncologist|May 27, 2020
Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker StudyRobert Wesolowski, Daniel G Stover, Maryam B Lustberg, et al.
JCO Precision Oncology|July 7, 2022
Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor BenefitRomualdo Barroso-Sousa, Juliet Forman, Katharine Collier, et al.
Pageof 15

Showing results (121-130 of 148) with videos related to

Sort By:
Pageof 15
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 8, 2024
Prevalence, Dynamics, and Prognostic Role of Clonal Hematopoiesis of Indeterminate Potential in Patients With Breast CancerStefania Morganti, Christopher J Gibson, Qingchun Jin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 17, 2019
Correction: ER<sup>+</sup> Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 InhibitorsAngel L Guerrero-Zotano, Thomas P Stricker, Luigi Formisano, et al.
Nature Communications|January 25, 2023
Author Correction: A framework for clinical cancer subtyping from nucleosome profiling of cell-free DNAAnna-Lisa Doebley, Minjeong Ko, Hanna Liao, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 28, 2018
ER<sup>+</sup> Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 InhibitorsAngel L Guerrero-Zotano, Thomas P Stricker, Luigi Formisano, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 4, 2018
Association of Cell-Free DNA Tumor Fraction and Somatic Copy Number Alterations With Survival in Metastatic Triple-Negative Breast CancerDaniel G Stover, Heather A Parsons, Gavin Ha, et al.
Nature Communications|December 3, 2022
A framework for clinical cancer subtyping from nucleosome profiling of cell-free DNAAnna-Lisa Doebley, Minjeong Ko, Hanna Liao, et al.
Nature Medicine|June 9, 2016
Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastasesJing Ni, Shakti H Ramkissoon, Shaozhen Xie, et al.
Cell Reports|November 24, 2016
CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast CancerShawn F Johnson, Cristina Cruz, Ann Katrin Greifenberg, et al.
The Oncologist|May 27, 2020
Phase I Study of Veliparib on an Intermittent and Continuous Schedule in Combination with Carboplatin in Metastatic Breast Cancer: A Safety and [18F]-Fluorothymidine Positron Emission Tomography Biomarker StudyRobert Wesolowski, Daniel G Stover, Maryam B Lustberg, et al.
JCO Precision Oncology|July 7, 2022
Multidimensional Molecular Profiling of Metastatic Triple-Negative Breast Cancer and Immune Checkpoint Inhibitor BenefitRomualdo Barroso-Sousa, Juliet Forman, Katharine Collier, et al.
Pageof 15